Global T-cell Lymphoma Market is estimated to be valued at US$ 1,627.1 million in 2021 and is expected to exhibit a CAGR of 9.8% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Key players involved in the market are focusing on launches and regulatory approvals of new drugs for treatment of T-cell lymphoma and this is expected to drive the market growth over the forecast period.
For instance, in August 2018, Kyowa Kirin Co., Ltd., a Japan based pharmaceutical company, received the U.S. Food and Drug Administration approval for its humanized monoclonal antibody Poteligeo (Mogamulizumab-kpkc) to be used in the treatment of T-cell leukemia, cutaneous T-cell lymphomas, and T-cell lymphomas in adult patients.
𝐓𝐨 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭: @ https://www.coherentmarketinsights.com/insight/request-sample/4799
Global T-cell Lymphoma Market – Impact of Coronavirus (Covid-19) Pandemic
COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 256 million cases and 5.1 million deaths due to Coronavirus (COVID-19) were reported up till November 21, 2021, across the globe.
The COVID-19 pandemic has negatively affected several markets across the globe and is also expected to hamper the demand and supply in global T-cell lymphoma market, owing to lockdowns, halt of clinical trials related to cancer and lack of labour involved in manufacturing of drugs. For instance, according to an article published by the Nepal Journal of Epidemiology in September 2020, COVID-19 pandemic has raised various challenges in the field of clinical research such as implementation of strict guidelines which restrict physical interaction between the participants of a clinical trial study and the clinical trial personnel, thus leading to halt of clinical trials during the COVID-19 pandemic.
Key players involved in the market are focusing on adoption of inorganic growth strategies such as partnership, acquisitions, and others to strengthen their position in the global T-cell lymphoma market. For instance, in June 2021, Orion Corporation, a Finland based pharmaceutical company, entered into a collaboration with Finnish Red Cross Blood Service, a Finland based provider of blood service, to develop new CAR (Chimeric antigen receptor) T-cell cancer therapy. CAR T-cell therapy can be used to treat patients with refractory or relapsed T-cell lymphoma, thus such collaborations are expected to fuel the growth of global T-cell lymphoma market.
𝐃𝐨 𝐘𝐨𝐮 𝐇𝐚𝐯𝐞 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐪𝐮𝐢𝐫𝐞𝐦𝐞𝐧𝐭? 𝐀𝐬𝐤 𝐓𝐨 𝐎𝐮𝐫 𝐄𝐱𝐩𝐞𝐫𝐭𝐬: https://www.coherentmarketinsights.com/insight/talk-to-analyst/4799
Key Takeaways of the Global T-cell Lymphoma Market:
- The global T-cell lymphoma market is expected to exhibit a CAGR of 9.8% over the forecast period, owing to increasing regulatory approvals of new T-cell lymphoma therapies. For instance, in November 2018, Seagen Inc., a U.S. based biotechnology company, received the U.S. FDA approval for its anticancer agent brentuximab vedotin (BV) for the treatment of previously untreated systemic anaplastic large cell lymphoma (a type of T-cell lymphoma) in adult patients.
- Among therapy, chemotherapy is projected to account for largest market share in 2021, owing to recent chemotherapy drug launches for the treatment of one or more types of T-cell lymphomas. For instance, in May 2021, Eisai Co., Ltd., a Japan based pharmaceutical company, announced the launch of its anticancer drug Remitoro (Intravenous Drip Infusion) in Japan for treatment of relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).
- Key players involved in the global T-cell lymphoma market include F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG, SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health Companies Inc.
𝐆𝐫𝐚𝐛 𝐭𝐡𝐞 𝐎𝐟𝐟𝐞𝐫 𝐚𝐧𝐝 𝐆𝐞𝐭 Upto 𝟑𝟎% 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐨𝐧 𝐓𝐡𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 𝟐𝟎𝟐𝟐-𝟐𝟎𝟐𝟖 @ https://www.coherentmarketinsights.com/promo/buynow/4799
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Lymphoma Type
- Market Snippet, By Therapy
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- PEST Analysis
- Regulatory Scenario
- Market Trends
- Key Highlights
- Reimbursement Scenario
- Mergers & Acquisitions
- Market Dynamics
- Global T-cell Lymphoma Market – Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- Impact on Clinical Trials and Drug Development
- Government Initiatives
- Global T-cell Lymphoma Market, By Lymphoma Type, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Peripheral T-cell Lymphoma
- Cutaneous T-cell Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Anaplastic Large Cell Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Angio-immuno-blastic T-cell Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- T-cell Lymphoblastic Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Cutaneous T-cell Lymphoma
- Introduction
- Global T-cell Lymphoma Market, By Therapy , 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Radiotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Stem Cell Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others (Antiviral Therapy, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/t-cell-lymphoma-market-4060
𝗔𝗯𝗼𝘂𝘁 𝗨𝗦:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗨𝘀:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837